Although there is evidence to suggest that PML/RARa expression is not the sole genetic event required for the development of acute promyelocytic leukemia (APL), there is little doubt that the fusion protein plays a central role in the initiation of leukemogenesis. The two therapeutic agents, retinoic acid and arsenic, that induce clinical remissions in APL, both target the oncogenic fusion protein, representing the ®rst example of oncogene-directed cancer therapy. This review focuses on the molecular mechanisms accounting for PML/RARa degradation. Each drug targets a speci®c moiety of the fusion protein (RARa for retinoic acid, PML for arsenic) to the proteasome. Moreover, both activate a common caspase-dependent cleavage in the PML part of the fusion protein. Speci®c molecular determinants (the AF2 transactivator domain of RARa for retinoic acid and the K160 SUMO-binding site in PML for arsenic) are respectively implicated in RA-or arsenic-triggered catabolism. The respective roles of PML/RARa activation versus its catabolism are discussed with respect to dierentiation or apoptosis induction in the context of single or dual therapies. Oncogene (2001) 20, 7257 ± 7265.
The players
Since the identi®cation of the PML/RARa fusion protein as the oncogene product of the t(15;17) translocation, a number of studies have addressed the biological bases of leukemogenesis. Like many other fusion proteins found in myeloid leukemias, PML/RARa is believed to exert a dual dominant negative function on each of the pathways regulated by its parental proteins (Rabbitts, 1994) . RARa is a ligand-activated transcriptional factor that, among other things, modulates myeloid cell dierentiation. RARa appears to have a dual role, to antagonize neutrophilic dierentiation in the absence of its cognate ligand, retinoic acid (RA), to shift immature cells towards a granulocytic lineage and accelerate their maturation in the presence of RA (Kastner et al., 2001) . PML is the organizer for nuclear subdomains of unknown function, PML NBs, which appear to modulate apoptosis sensitivity. This scheme may be somehow oversimpli®ed since RA may directly trigger apoptosis (Altucci et al., 2001 and reference therein) and PML be implicated granulocytic/ monocytic dierentiation, possibly through an eect on RA-dependent transcriptional control (Wang et al., 1998b) .
Type II nuclear receptors have a dual function: in the absence of ligand, they tether corepressors and histone deacetylases onto genes harbouring their response element, thus inducing their silencing. Upon ligand binding, this complex is replaced by coactivators and histone acetyl-transferase that will open up the chromatin and activate the transcription of target genes. There is evidence that PML/RARa binds more tightly to the corepressor complex, most likely because PML/RARa is present as homodimers which have two strong binding sites for these corepressors. The PML/ RARa bound transcriptional repressor complex requires a higher concentration of retinoic acid (RA) to be released and be replaced by the activator complex. That transcriptional repression plays a key role in APL pathogenesis is outlined by the eects of histone deacetylase inhibitors to restore dierentiation in cell lines, animal models of the disease or even patients (Lin et al., 1998; Warrell et al., 1998 ) (see accompanying reviews).
Expression of the fusion protein, which is ®rmly DNA-bound induces PML delocalization through PML//PML/RARa heterodimers and recruitment of the PML partners onto the chromatin (Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) . This has been proposed to interfere with PML function. Indeed, a number of reports have shown that PML/RARa expression induces apoptosis resistance (Wang et al., 1998a) . Conversely, targeting of a variety of proteins (such as Daxx or p53) onto NBs by sumolated PML was proposed to sensitize the cell to apoptosis (Ferbeyre et al., 2000; Pearson et al., 2000; Torii et al., 1999; Zhong et al., 2000b) .
Retinoic acid and arsenic each induce complete remissions in APL patients (see reviews by L Degos and Z Chen). The ability of RA to promote APL cell dierentiation ex vivo and in vivo is well established. Arsenic trioxide was initially proposed to trigger apoptosis ex vivo, although later studies have shown that it can also induce non-terminal dierentiation (Chen et al., 1996 . In vivo, either in treated patients or in animal models of the disease, both dierentiation and apoptosis appear to take place and it is dicult to evaluate the respective contribution of each of these processes to disease remission (Lallemand-Breitenbach et al., 1999) . PML/RARa targeting by RA: activation, degradation or both?
Numerous studies have shown that RA can bind to PML/RARa and activate transcription through the fusion protein, although not as eciently as RARa (Grignani et al., 1993; Nervi et al., 1992) . Moreover, mutations in the RA-binding or AF-2 activation domains of PML/RARa are found in patients that are clinically resistant to RA, consistent with the idea that the dierentiating eect of RA in APL is mediated through transcriptional activation upon its binding to the fusion protein. Transcriptional activation through the fusion protein is clearly an ecient way to relieve the repression imposed onto key target genes by the fusion protein. Yet this may not be the only way out, as induction of PML/RARa catabolism appears to be a common property of the two speci®c APL therapies.
Induction of PML/RARa catabolism by RA was demonstrated long after the identi®cation of the therapeutic eect of RA on the disease. The rate of catabolism of the fusion protein is quite variable (Duprez et al., 1996a,b; Jansen et al., 1995; Raelson et al., 1996; Yoshida et al., 1996; Zhu et al., 1997 Zhu et al., , 1999 . Degradation of the fusion protein is clearly responsible for the RA-induced relocalization of PML (and associated NB proteins) (Daniel et al., 1993; Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) , which could promote apoptosis induction. Indeed, RA triggers apoptosis in some PML/RARa transgenic mice (Grisolano et al., 1997) . Some evidence suggests that degradation of the fusion ocurs on DNA and that NB-associated proteins are secondarily released to reform NBs: there is little if any targeting of PML/RARa onto NBs during RA treatment (Dyck et al., 1994; Koken et al., 1994; Nervi et al., 1998) . Moreover, when RA-induced degradation is blocked by proteasome inhibitors, PML/RARa remains microspeckled, in contrast to arsenic treated cells (Lallemand-Breitenbach et al., 2001, see below) .
A ®rst mechanistical analysis demonstrated that caspase activation was responsible for cleavage of the fusion protein , accounting for the appearance of a de novo 90 kD protein upon RA exposure (Duprez et al., 1996a; Gianni et al., 1998; Jansen et al., 1995; Raelson et al., 1996; Zhu et al., 1999) . The speci®c cleavage site was mapped to the Cterminus of PML (D522). Accordingly, PML was shown to be a caspase target during the executor phase of apoptosis (Quignon et al., 1998; Zhu et al., 1999) . Since several caspases become activated during hematopoietic cell dierentiation independently of cell death induction , this cleavage likely re¯ects an ongoing dierentiation and is accordingly not observed in RA-resistant cell-lines. Interestingly, this caspase site is located in between bcr1 and brc2 breakpoints. Therefore caspase cleavage of the fusion is predicted to occur only in a subset of APLs and could account for the dierent behaviors of the fusion proteins, either in clinical outcome or transduction of RA-response (Huang et al., 1993; Slack and Yu, 1998 ). Yet, caspase activation on its own could not account for RA-induced degradation of the fusion because a point mutant on the cleavage site is still degraded (PG Pelicci, personal communication). Moreover, the sole involvement of caspase was dicult to reconcile with the observation that proteasome inhibitors revert PML/RARa catabolism (Yoshida et al., 1996) .
A second pathway of PML/RARa degradation was outlined a year later with the observation that RARa or any RARa fusion protein, are degraded by the ubiquitin/proteasome system upon RA activation (Zhu et al., 1999; Kopf et al., 2000) . The DNA-bound, functional RAR/RXR heterodimer appears to be degraded in an AF-2-dependent manner. Therefore, the domains implicated in catabolism are also required for transcriptional activation, suggesting that activation and catabolism are molecularly coupled. Target gene activation is not required for catabolism (Zhu et al., 1999) . The activated AF-2 domain was previously shown to bind the SUG-1 component of the proteasome 19 S complex vom Baur et al., 1996) , providing a direct link between AF-2 activation and the proteasome-dependent degradation ( Figure 1 ). Not surprisingly, given the universal use of the AF-2 domain in nuclear receptors, such ligand-induced nuclear receptor catabolism has been described for a number of them (ERa, PPARg, PR. . . . (Kopf et al., 2000; Lonard et al., 2000; Hauser et al., 2000) and references therein). That the molecular determinants involved in gene activation and receptor catabolism are identical precludes a genetic analysis of their respective contribution to dierentiation.
How does degradation relate to target gene activation? Several hypotheses can be put forwards. Either degradation occurs to limit target gene activation, as a classical feedback mechanism. Alternatively protein catabolism, possibly including that of the nuclear receptor itself, could be required for transcriptional activation, as was recently suggested for a variety of nuclear receptors (Lonard et al., 2000; Perletti et al., 2001 ; M Gianni and C Rochette-Egly, personal communication) or other transcriptional activators (Stitzel et al., 2001; Thomas and Tyers, 2000) . Recent evidence points to unsuspected links between proteasome components and transcription activation. First, proteasome subunits have been found in a variety of transcription-associated protein complexes (Thomas and Tyers, 2000) . Second, nuclear receptors were shown to have rapid association/dissociation from their DNA targets, a process blocked by proteasome inhibitors which immobilize them on the nuclear matrix (Shang et al., 2000; Stenoien et al., 2001) . Third, the CBP coactivator appears to be required for mdm2 mediated, proteasome-dependent p53 degradation (Grossman et al., 1998) . A fourth connection comes from the immediate-early protein ICP0 from HSV-1, a broad transcriptional activator, required for the shift from viral latency to productive infection, that has an E3 activity and induces the degradation of many proteins (see review by R Everett). In that setting again, proteasome inhibitors can block both transcription activation and ICP0-induced viral reactivation (Everett et al., 1998) . Altogether, it appears that transcriptional activation and proteolysis may have more connexions than previously thought.
Arsenic targeting of PML: implications for APL, NB formation and function
Similar to RA, studies on the cellular and molecular eects of arsenic only started after the demonstration of its clinical ecacy in APL (Chen et al., 1996; . Initial studies suggested that therapeutic doses of arsenic induced apoptosis, although later ones demonstrated induction of non-terminal dierentiation (Chen et al., 1996 . Several studies have demonstrated that selenium, by protecting against oxydative stress, dramatically reduces arsenic-induced apoptosis (Gianni et al., 1998; Jing et al., 1999 and D. Vitoux, manuscript in preparation) . Since the selenium concentration in vivo is 10-fold higher than in cell culture, we suggest that massive arsenic-induced apoptosis is, at least in part, a cell-culture artefact. That terminal dierentiation occurs in vivo, but not ex vivo, could similarly be due to the presence in vivo of dierentiating growth factors, such as G-CSF, GM-CSF or stem cell factor (Kinjo et al., 2000) , V Lallemand and M Roussel, manuscript in preparation). Moreover, several groups have found that in the APL cell-line NB4, combining arsenic and high dose cAMP triggers terminal dierentiation (Z Chen, personal communication; D Vitoux and H de TheÂ , manuscript in preparation), providing a major indication that the primary action of arsenic in vivo is likely to be dierentiation.
Arsenic modulates the microspeckled pattern of PML distribution within the nucleus of APL cells and induces the rapid reformation of PML NBs (Chen et al., 1996; Muller et al., 1998; Shao et al., 1998; Zhu et al., 1997) . As RA, arsenic targets PML/RARa for degradation Muller et al., 1998; Zhu et al., 1997) providing a striking similarity in the eect of these two otherwise unrelated agents . It was rapidly found that, in contrast to RA, which targets the RARa moiety of the fusion, arsenic targets its PML moiety . Analyses of the PML/RARa degradation pathways have implicated both the proteasome and caspases. Arsenic has a profound impact on the intranuclear distribution of the PML protein, forcing the nucleoplasmic fraction of PML onto the nuclear matrix in large, abnormal NBs (Muller et al., 1998; Zhu et al., 1997) , where some studies have found PML, like PML/RARa, to be degraded (Lallemand-Breitenbach et al., 2001; (Figure 2) .
Arsenic induces covalent modi®cations of the PML protein by the ubiquitin-related peptides SUMO (Lallemand-Breitenbach et al., 2001; Muller et al., 1998; Zhu et al., 1997) . Sumolation is required for the targeting of NB-associated protein onto NBs (Ishov et al., 1999; Lallemand-Breitenbach et al., 2001; Zhong et al., 2000a) and was proposed to be implicated in PML targeting on the nuclear matrix (Muller et al., 1998) . Recent studies have demonstrated that, upon arsenic exposure, PML targeting onto the nuclear matrix occurs independently of sumolation. Moreover, arsenic-induced sumolation (a most likely polysumolation, as SUMO-2 contains a speci®c sumolation site) on a speci®c lysine residue is required for both PML and PML/RARa degradation (Lallemand-Breitenbach , 2001) . In striking parallelism to the situation outlined for RA (where the activated AF2 domain recruits the SUG-1 component of the 19S proteasome), this speci®c sumolation site is required for the recruitment of the 11S proteasome regulatory complex. Therefore, arsenic has a dual eect: targeting PML and associated proteins onto NBs and degrading PML/ RARa, strikingly similar to RA that induces both transcriptional activation and PML/RARa degradation. These two eects of arsenic on PML rely on the same molecular determinants (K-160 sumolation site, similar to AF-2 for RA), again precluding a genetic analysis of the respective contribution of these two events to arsenic action.
A dierent image of NB assembly emerges from these studies: PML, initially present in the chromatin, will be targeted onto the nuclear matrix in reponse to a variety of stimuli (arsenic exposure or cell cycle progression (Everett et al., 1999; M Lei, manuscript in preparation) . This will yield small nuclear matrix aggregates that are distinctly full (Figure 2) . A second step, that we propose to name maturation, occurs as SUMO is covalently bound onto PML. This results in the recruitment of interacting proteins (Daxx, Sp100. . . . and the proteasome 11S complex), together with sharp morphological changes. Indeed, mature PML NBs become characteristically shell-like and PML forms the outer shell of the structure, while other proteins (Sp100, SUMO. . . ) are found in the central electron clear core (M Koken and F Puvion, manuscript in preparation). Since only sumolated PML will be degraded upon arsenic exposure, will recruit proteasome components and form mature bodies, we propose that mature PML NBs could be sites of catabolism, at least for PML or PML/RARa upon arsenic exposure (Lallemand-Breitenbach et al., 2001) .
The 11S proteasome comprises a,b, or g polypeptides arranged in a ring of six subunits. This complex was proposed either to facilitate 20S-mediated catabolism (in the context of peptide cleavage prior to antigen presentation), or to facilitate the refolding of misfolded proteins by HSP 90 (Minami et al., 2000) . Intriguingly, the a and b subunits are primary targets genes of interferon g, like PML and Sp100 (Groettrup et al., 1995; Stadler et al., 1995) . It is possible that the 11S complex is directly responsible for recruiting proteins that can be targeted onto PML NBs, particularly upon overexpression, or upon de®ned cellular stresses (see review by G Maul). In that sense, PML NBs were shown to be disorganized during many viral infections. This link between PML bodies and the imunoproteasome could account for a number of apparently contradictory observations, such as the susceptibility of PML7/7 mice to infections or the frequent colocalisation of PML and overexpressed/misfolded proteins (Fabunmi et al., 2001; Guiochon-Mantel et al., 1995; Skinner et al., 1997; Wang et al., 1998a) .
What are the functional consequences of PML/RARa degradation in APL cells?
Unliganded RARa is a repressor that, in myeloid cells, signi®cantly slows down dierentiation. Studies on some nuclear receptors have shown that suppressing the hormone generates a much more severe phenotype than knocking out the receptors (Kastner et al., 2001; J Samarut, personal communication) . This has been interpreted to say that while absence of a receptor is neutral as regards target gene activation, absence of physiological levels of the ligand transforms endogenous nuclear receptors into potent transcriptional repressors of those same targets. In fact, overexpression of normal RARa was shown to block myeloid dierentiation is several settings (Du et al., 1999; Grignani et al., 1996) . The abundant PML/RARa protein, which is a more potent repressor than RARa, is similarly expected to impair myeloid dierentiation. Therefore, degradation of the PML/RARa fusion protein is most likely to have major eects on transcription and dierentiation (Figure 3) . Do we only need to bypass repression, or is overactivation required? Some genes are principally activated through AF1 rather than AF2, suggesting that the potency of the hormone-dependent activation function may be variable from promotor to promotor. We had proposed that RA-induced, AF-2 dependent, degradation of the normal RARa could derepress targets independently of an AF-2-dependent transcriptional activation (Zhu et al., 1999) . Taken that the molecular determinants in the receptor required for coactivator binding and degradation are very similar, if not identical (vom Baur et al., 1996; Zhu et al., 1999) , it may not be so easy to discriminate between the activation and the derepression models. Assuming that derepression through degradation is indeed critical for dierentiation induction, arsenic, which selectively degrades PML/RARa, could act through the same process. A combinaition of the two mechanisms (derepression through degradation for RA and arsenic) and direct transcriptional activation (for RA exclusively) could be imagined (Figure 3 ). In the case of RA, dierent schemes can be imagined depending on whether the principal eect of RA is to induce activation or degradation of the fusion protein.
A number of indications point to a two-step model in induction of APL cell dierentiation, initially developed as priming and maturing by M. Lanotte (Ruchaud et al., 1994) . We suggest that the ®rst event, priming, corresponds to the derepression of a critical target gene repressed by PML/RARa (Figure 4) . If the expression of this gene is high enough, dierentiation will ensue. If this gene is expressed at intermediate levels, then additional signaling is required, for example by cAMP, G-CSF or histone desacetylase inhibitors (Quenech 'Du et al., 1998) . A similar two-step mechanism accounts well for`rexinoid'/cAMP-dependent NB4 cell maturation, for which RXR-speci®c signaling could bypass and PML-RARa repression of critical priming-genes (Benoit et al., 1999) . Note that such derepression is strong enough to allow cAMP to trigger maturation of the ATRA-resistant NB4-R2 cells, even though a mutated PML-RARa acts as a super-repressor (Duprez et al., 2000) . This simple twostep model clearly accounts for the fact that either full dose arsenic or low dose retinoic acid triggered dierentiations are non-terminal and that adding cAMP or G-CSF then promotes terminal dierentiation, strongly supporting a model where derepression of a ®rst set of genes has a permissive role on dierentiation (Figure 4) .
Two additional elements may complicate this model. First, PML/RARa is well known to bind DNA sequences which are not canonical RARE. Hence PML/RARa may repress genes which are normaly controlled by Vitamin D3 or PPAR ligands (Jansen et al., 1995; Perez et al., 1993) , or even non nuclear receptor target genes. As a result of PML/RARa binding, transcription of these genes is likely to be repressed, but may also become RA-activated. In that sense, transglutaminase, LAP and p21 were shown to be preferential PML/RARa target genes (Casini and Pelicci, 1999; Gianni' et al., 1995) . Second, on canonical RAREs, there is a dynamic balance between PML/RARa and RARa binding. Since unliganded PML/RARa is a more potent repressor than RARa, the ratio between these two proteins is critically important. RARa2 is RA-induced, while PML/RARa is not, likely accounting for the much faster decrease of PML/RARa expression compared to that of RARa (Chomienne et al., 1991; Nervi et al., 1998; Raelson et al., 1996; Yoshida et al., 1996; Zhu et al., 1999) . Therefore, upon PML/RARa degradation, RARa could bind to the same response element to activate gene expression. This last phenomenon may account for some of the observed arsenic/RA synergies (Gianni et al., 1998; Lallemand-Breitenbach et al., 1999) . Indeed, as arsenic degrades PML/RARa, RARa comes to activate the critical targets (Figure 3) . Finally, one cannot exclude that PML/RARa exerts a transdominant negative action by protein/protein interactions, through the silencing of another transcription factor. The above-mentioned issues are not encountered with rexinoid'-priming and APL-maturation, since here, according to a two-step model, PML-RARa degradation is not required, and neither RARE-dependent signaling is involved (Benoit et al., 1999) .
The AF-2 dependent RARa-targeted degradation process is common to all APL-associated fusion proteins. For example, degradation of the t(11,17)-associated PLFZ/RARa fusion was observed in transiently transfected cells, with primary APL cells from a patient, as well as in vivo in a transgenic mouse model of the disease Rego et al., 2000) . Yet, this speci®c APL does not respond to RA by terminal dierentiation, although some RAtriggered changes are observed ex vivo or in vivo Rego et al., 2000) . These observations raise an intriguing issue: how can a cell remain leukemic having completely degraded its oncogene? It is plausible that the very low levels of PLZF/RARa remaining in the cell are sucient for transformation or that PLZF/RARa induces some irreversible events in the cell, for example at the chromatin level. Yet, these APL associated to the variant t(11;17) translocation are not completely insensitive to RA as very high doses of RA, or combining RA to GM-CSF or histone desacetylase inhibitors were shown to induce dierentiation in RAresistant t(11;17) associated APL (Jansen et al., 1999; Kitamura et al., 2000) . We suggest that in these cases, PLZF/RARa degradation facilitated the response to other stimuli.
Synergy or antagonism or RA/arsenic associations?
The question of synergy versus antagonism has been controversial, at least in cell lines (Chen et al., 1996; Gianni et al., 1998; Jing et al., 2001; Shao et al., 1998 ). Yet, in animal models of APL, a clear synergy was always observed (Jing et al., 2001; Lallemand-Breitenbach et al., 1999; Rego et al., 2000) . One possible clue to these discrepancies is to assume that apoptosis induction in cell lines does not re¯ect the action of arsenic in vivo. Indeed, no synergy for dierentiation can be observed if the cell is dying from oxydative stress. If the major eect of arsenic is to induce dierentiation, then an additive or synergistic eect is to be expected, possibly as the consequence of arsenicinduced degradation of the fusion protein together with Figure 3 Schematic representation of the eects of RA and arsenic on canonical RARE (direct repeats, DR5/DR2) (blue) or uncharacterized PML/RARa binding sites (orange). Two models are shown depending on the respective importance of RA-induced PML/RARa transcriptional activation or degradation Therapy-induced oncogene degradation J Zhu et al RA-induced RARa activation. Recent trials demonstrate that this association is well tolerated, at least in relapse patients. The small number of patients, all previously heavily exposed to RA, precludes a comparaison of the relative rates of disease clearance in vivo by arsenic or combined RA/arsenic (H Dombret, personal communication). The most dramatic eect of dual treatments in mice is not to increase the rate of dierentiation, it is to prolong survival (Lallemand-Breitenbach et al., 1999) . This can be interpreted as a simple enhancement of RA potency or as a classical model of eradication by non-cross resistant agents. It has often been proposed that cancer eradication cannot occur without an immune clearance of the cancer cells. In parallel to induction of dierentiation, arsenic also promotes some apoptosis/ necrosis in vivo. Necrotic cells were shown to promote an immune response, while apoptotic bodies favor tolerance (Voll et al., 1997) . That in patients, arsenic as a single agent can cure APL could indeed suggest that this agent can promote an anti-leukemia immune response.
APL is an extraordinary model: most patients are cured, the molecular pathogenesis seems understood, appealing models for therapy have been proposed. But can these concepts be generalized? Arsenic was shown to induce the speci®c degradation of a series of oncogenes, in particular viral ones (Hamadeh et al., 1999; Puccetti et al., 2000; Yih and Lee, 2000; Zheng et al., 1999) . The best studied exemple is another leukemia, acute T cell leukemia (ATL), where infection by a virus, HTLV-I leads to the expression of a virally encoded transactivator protein, Tax that activates a large number of cellular genes, including the NF-kB survival pathway and an IL2 autocrine loop. Arsenic will induce the death of these cells (Bazarbachi et al., 1999) and tax catabolism through the proteasome (ElSabban et al., 2000) . Arrays analyses demonstrate that most of the genes rapidly down-regulated by arsenic are indeed NF-kB targets, implying that Tax degradation rapidly shuts o this network of anti-apoptotic genes and providing a plausible explanation for cell death induction (A Bazarbachi and H de TheÂ , manuscript in preparation). Similarly, speci®c inhibitors of the abl kinase have recently made their way to the clinic. Therefore, oncogene-targeted therapy may not be restricted to APL.
